Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 8-K (Current Report)
Date of Report: September 19, 2003
Event: Acquisition of substantially all assets of BioRobotics Limited and BioRobotics Group Limited (collectively "BioRobotics") by Genomic Solutions Inc., a wholly-owned subsidiary of HBIO.
Key Financial Metrics
- Purchase Price: Approximately $3.2 million.
- Payment Structure: Paid partly in cash and partly through the assumption of certain limited liabilities.
- Funding Source: General working capital.
- Escrow Amount: $250,000 deposited to secure indemnification obligations, held for 9 months post-closing.
- Accounting Treatment: Purchase transaction.
- Revenue/Profit/Cash Flow: The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for HBIO or the acquired entity at this time.
Material Changes
The primary material change is the expansion of HBIO's asset base through the acquisition of BioRobotics. BioRobotics previously designed, developed, manufactured, and distributed life science instrumentation for DNA microarray manufacturing and colony picking. Genomic Solutions intends to continue utilizing these assets for the same purposes. The transaction was negotiated at arm's length with no material relationships between the parties prior to the deal.
Guidance, Outlook, and Risks
- Outlook: Genomic Solutions plans to continue using the acquired assets for life science instrumentation.
- Forward-Looking Statements: The filing contains forward-looking statements subject to known and unknown risks. Actual results may differ materially from anticipated results.
- Missing Financial Data: Financial statements of the acquired business and pro forma financial information are not included in this report. They are scheduled to be filed by amendment no later than December 5, 2003.
- Risks: Referenced risks are detailed in the "Important Factors That May Affect Future Operating Results" section of HBIO's 2002 Form 10-K.
Investor Verification Checklist
- Verify the final financial statements of BioRobotics once filed by amendment (expected by December 5, 2003).
- Review the pro forma financial information to understand the impact of the acquisition on HBIO's consolidated results.
- Confirm the specific amount of liabilities assumed as part of the $3.2 million purchase price.
- Monitor the status of the $250,000 escrow account over the 9-month holding period.
- Review the full Asset Purchase Agreement (Exhibit 2.1) for detailed terms and conditions.